They go on a lot, since stock options are a big part of compensation. Driscoll sold 4800 shares at $17.20 in the past few days. I would have thought that since 10-Q has not been released, this would not be permitted.
Very upbeat after very good results. A strong suggestion they will raise guidance after 2nd quarter. Still 5 million in free cash flow for the year doesn't seem that great, and there is a suggestion that the shift in first aid requirements to ANSI 2015 is a short term help.
Thanks. For anyone else looking, click on the 2nd entry under Steel Partners in Edgar.
Note removal of postings by people shilling, apparently, for lawyers suing about buy out. At the same time,it is possible an auction would have garnered a higher price, but I have been skeptical the lawsuits will benefit anyone besides the lawyers.
RBC Capital Markets lowers its rating on Autoliv (NYSE:ALV) to Underperform.
The investment firm chops its price target on the automobile industry supplier to $96 which implies a 15% slide in share price.
Steve, when I tried to join investor village they wanted info that had me concerned. Do you get a lot of email from them or any other problems?
Interesting. You have just joined Yahoo message boards so this is your only post. Mr. Tedkov has been a member since July 2014, and his/her only other post, back when he joined, was about a lawsuit against another take over.
From a cursory look, it does not appear that Gabelli is a major shareholder of HNH. Hence, if he does not contest the offer, then I will have to think it is reasonable.
I wonder if any of us would have taken $34 offer more seriously, and possibly bought more stock, if not for the previous debacle. Big question: is Gabelli going to be satisfied, or has he already blessed the deal?
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that new data on patients at intermediate risk for open-heart surgery demonstrated that transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve was superior to surgery at one year on a composite primary endpoint of mortality, stroke and moderate or severe aortic regurgitation. In addition, the SAPIEN 3 valve demonstrated clinical superiority at one year on individual assessments of all-cause mortality and of stroke.
I assume the following, if it becomes an actual treatment, would require open heart surgery, and would be more common than a transplant:
In this Lab at the University of Tel Aviv, the future of heart medicine is taking shape. Researchers have developed a bionic patch that can monitor and treat heart conditions in real time. (SOUNDBITE) (English) PROFESSOR TAL DVIR OF TEL AVIV UNIVERSITY'S DEPARTMENT OF BIO TECHNOLOGY, DEPARTMENT OF MATERIAL SCIENCE AND ENGINEERING AND THE CENTER FOR NANO TECHNOLOGY, SAYING: "Well, this is the first time that engineered tissue, thick engineered tissue, functional tissues, are integrated with electronics to become cyborg tissues, meaning that there is integration of machine and living tissues." That integration could potentially give doctors new options when treating a myriad of heart problems. The patch is comprised of live, lab-grown heart tissue and nano electronics embedded on a 3D printed scaffold. The team says the patch could offer an alternative to heart transplantation in the future by releasing medications as well as repopulating the defected area with cells that are capable of contraction. In the short term, the device could monitor and activate the entire organ as needed as well as alert a doctor to a potentially fatal problem in real time. (SOUNDBITE) (English) PROFESSOR TAL DVIR OF TEL AVIV UNIVERSITY'S DEPARTMENT OF BIO TECHNOLOGY, DEPARTMENT OF MATERIAL SCIENCE AND ENGINEERING AND THE CENTER FOR NANO TECHNOLOGY, SAYING: "The patient is sitting in his house and not feeling well and the physician immediately sees the condition of the heart on his computer and can remotely activate the heart: can provide electrical stimulation, can release drugs. And if you really think about this technology, we don't even need a physician because the cardiac patch can regulate its own function." As exciting as it may be, the bionic heart patch is still years from commercial viability.
Their experience with the old fresh and light was that their marketing did not pay off, whereas they were increasingly successful with private label. Now, once again they are planning to compete more vigorously in the brand space with a marketing push, the very same strategy which did not work last time. Perhaps it will work this time.
Do you know the potential for Loon? Apparently, Google is implementing a full scale project to bring good internet to Sri Lanka, and according to Business Week the next major source of business may be Indonesia.
Picker, thanks for the reporting. If you go to their on-line site, you will find 29 entries for ACU brands, and 5 for Fiskar. Does Fiskar have other brands? Apparently ACME scissors are not supplied by ACU
Included in comprehensive income (but not gaap income) is 647K from unrealized hedging gains. Now KTCC hedges against gains in Mexican peso, but since peso has been going down, I would expect losses from the hedging. Explanation?